Xencor, Inc Impairment of Intangible Assets (Excluding Goodwill)
Xencor, Inc (XNCR) reported Impairment of Intangible Assets (Excluding Goodwill) of $800.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill · last filed 2026-08-05
- Xencor, Inc impairment of intangible assets (excluding goodwill) for the quarter ending 2026-06-30 was $800.00K, a 57.89% decline year-over-year.
- Xencor, Inc impairment of intangible assets (excluding goodwill) for the quarter ending 2025-12-31 was $900.00K.
- Xencor, Inc impairment of intangible assets (excluding goodwill) for the quarter ending 2025-09-30 was $1.60M.
- Xencor, Inc impairment of intangible assets (excluding goodwill) for the quarter ending 2025-06-30 was $1.90M.
- Xencor, Inc impairment of intangible assets (excluding goodwill) for fiscal 2025 was $9.20M.
| Period end | Impairment of Intangible Assets (Excluding Goodwill) 3 month | Impairment of Intangible Assets (Excluding Goodwill) 6 month | Impairment of Intangible Assets (Excluding Goodwill) 9 month | Impairment of Intangible Assets (Excluding Goodwill) 12 month |
|---|---|---|---|---|
| 2026-06-30 | $800.00K 10-Q · filed 2026-08-05 | $800.00K 10-Q · filed 2026-08-05 | ||
| 2025-12-31 | $900.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $2.50M derived: sum of 2 quarters · filed 2026-02-25 | $4.40M derived: sum of 3 quarters · filed 2026-08-05 | $9.20M 10-K · filed 2026-02-25 |
| 2025-09-30 | $1.60M 10-Q · filed 2025-11-05 | $3.50M derived: sum of 2 quarters · filed 2026-08-05 | $8.30M 10-Q · filed 2025-11-05 | |
| 2025-06-30 | $1.90M 10-Q · filed 2026-08-05 | $6.70M 10-Q · filed 2026-08-05 | ||
| 2025-03-31 | $4.90M 10-Q · filed 2026-05-06 | |||
| 2024-09-30 | $0.00 10-Q · filed 2025-11-05 | $0.00 derived: sum of 2 quarters · filed 2025-11-05 | $0.00 10-Q · filed 2025-11-05 | |
| 2024-06-30 | $0.00 10-Q · filed 2025-08-06 | $0.00 10-Q · filed 2025-08-06 | ||
| 2024-03-31 | $0.00 10-Q · filed 2025-05-07 | |||
| 2023-09-30 | $0.00 10-Q/A · filed 2025-02-24 | $0.00 derived: sum of 2 quarters · filed 2025-02-24 | $0.00 10-Q/A · filed 2025-02-24 | |
| 2023-06-30 | $0.00 10-Q/A · filed 2025-02-24 | $0.00 10-Q/A · filed 2025-02-24 | ||
| 2023-03-31 | $0.00 10-Q/A · filed 2025-02-24 | |||
| 2022-09-30 | $0.00 10-Q · filed 2023-11-08 | $0.00 derived: sum of 2 quarters · filed 2023-11-08 | $0.00 10-Q · filed 2023-11-08 | |
| 2022-06-30 | $0.00 10-Q · filed 2023-08-03 | $0.00 10-Q · filed 2023-08-03 | ||
| 2022-03-31 | $0.00 10-Q · filed 2023-05-08 | |||
| 2021-09-30 | $400.00K 10-Q · filed 2022-11-07 | $400.00K derived: sum of 2 quarters · filed 2022-11-07 | $400.00K 10-Q · filed 2022-11-07 | |
| 2021-06-30 | $0.00 10-Q · filed 2022-08-03 | $0.00 10-Q · filed 2022-08-03 | ||
| 2021-03-31 | $0.00 10-Q · filed 2022-05-05 | |||
| 2020-09-30 | $0.00 10-Q · filed 2021-11-08 | $0.00 derived: sum of 2 quarters · filed 2021-11-08 | $0.00 10-Q · filed 2021-11-08 | |
| 2020-06-30 | $0.00 10-Q · filed 2021-08-04 | $0.00 10-Q · filed 2021-08-04 | ||
| 2020-03-31 | $0.00 10-Q · filed 2021-05-05 | |||
| 2019-09-30 | $0.00 10-Q · filed 2020-11-06 | $0.00 derived: sum of 2 quarters · filed 2020-11-06 | $0.00 10-Q · filed 2020-11-06 | |
| 2019-06-30 | $0.00 10-Q · filed 2020-08-05 | $0.00 10-Q · filed 2020-08-05 | ||
| 2019-03-31 | $0.00 10-Q · filed 2020-05-08 | |||
| 2018-09-30 | $0.00 10-Q · filed 2018-11-05 | $0.00 derived: sum of 2 quarters · filed 2019-08-07 | $0.00 10-Q · filed 2019-11-05 | |
| 2018-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-07 | $0.00 10-Q · filed 2019-08-07 | ||
| 2018-03-31 | $0.00 10-Q · filed 2019-05-09 | |||
| 2017-09-30 | $0.00 10-Q · filed 2018-11-05 | $0.00 10-Q · filed 2018-11-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |